

Media Release

New Clinical Data on the Topical Application of PENTRA®Bodies to be Presented at the 44th Annual ESDR Meeting

Schlieren/Zurich, September 2, 2014 - Delenex Therapeutics AG, a clinical stage biopharmaceutical company primarily developing treatments for dermatologic diseases using its proprietary PENTRA®Bodies, today announced that Prof. Dr. Georg Stingl from the Medical University in Vienna, Austria will present a late-breaking poster on new clinical data of DLX105 at this year's European Society for Dermatological Research Meeting in Copenhagen, Denmark. DLX105 is an anti-TNF α PENTRA®Body based on Delenex' proprietary antibody platform that is applied topically to the skin of mild to moderate psoriasis patients.

The poster (LB011) "Topical administration of the single-chain anti-TNF α antibody DLX105 suppresses TNF α and Th17 cytokines in psoriatic skin" will be presented on Thursday, September 11, 2014, at 6:30 PM in the late-breaking poster area at the Tivoli Congress Center in Copenhagen, Denmark.

Further information can be found on the ESDR 2014 website <http://www.esdr2014.org/>.

About Delenex Therapeutics AG

Delenex is a privately-held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics. Delenex aims at extending the benefits of proven antibody therapeutics to a much larger number of people suffering from psoriasis, hidradenitis suppurativa, acne and other, dermatological and non-dermatologic, diseases. Delenex' proprietary PENTRA®Bodies are small, highly potent and stable antibody fragments that are superior in penetrating tissues and in crossing barriers in the human body. Delenex was founded in September 2009 as a spin-off from ESBAtech (now a Novartis company).

For further details please contact:

Jakob Schlapbach, CFO
Delenex Therapeutics AG
Wagistrasse 27
CH-8952 Schlieren
E-mail: jakob.schlapbach@delenex.com
Website: www.delenex.com